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LAw, PoLICY, AND MARKET IMPLICATIONS OF 
GENETIC PROFILING IN DRUG DEVELOPMENT 
Michael J. Malinowski* 
INTRODUCTION 
Completion of a map of the human genome1 and the explosive 
emergence of a multitude of complementary technologies ranging 
from DNA chips (commonly referred to as ''biochips")2 to sophisti­
cated software have transformed· great expectations for genetic 
n1edicine into goals potentially obtainable in the foreseeable future.3 
* Emest and Iris Eldred Associate Professor of Law Science, and Public Health, Paul M. 
Hebert Law Center, Louisiana State University. This article originated in presentations 
made at the University of Arizona College of Pharmacy in February 2001 and at the Loui­
siana State University in February 2002. The author would like to thank those who partici­
pated in these forums and shared their comments. The author also would like to thank his 
students at Hofstra University School of Law during the spring 2002 semester for interac­
tions that enriched this article. This article was submitted for publication in April 2002, 
and does not necessarily reflect events thereafter. 
1 On June 26, 2000, U.S. government-led and privately funded teams of scientists jointly 
announced their completion of a rough map of the human genome. See What's News 
World-Wide, WALL ST. J. EuR., June 27, 2000, available at 2000 WL-WSJE 21064884. See gener­
ally 291 SCI. 1145 (February 16, 2001) (issue entitled ''The Human Genome"); 409 NATURE 
745 (Feb. 15, 2001) (issue dedicated to the release of a draft map of the human genome). 
See also International Human Genome Sequencing Consortium, Initial Sequencing and Analysis of 
the Human Genome, 409 NATURE 860, 872 fig. 9 (Feb. 15, 2001) (draft map of the human 
genome); Michael D. Lemonick, The Genome is Mapped. Now What?, TIME, July 3, 2000, at 
24-29. Information about the Human Genome Project may be obtained from the Internet 
site of the National Human Genome Research Institute (NHGRI), available at www.nhgri. 
nih.gov (last visited Mar. 24, 2002). 
2 For a discussion of DNA chip technology and how it is accelerating drug development 
that is readily accessible to non-scientists, see CYNTHIA ROBBINS-ROTH, FROM ALCHEMY TO 
IPO: THE BusiNESS oF BIOTECHNOLOGY 73-78, 225 tbl. 8.1 (Perseus Publishing, 2000). 
3 For discussion of the range of enabling technologies being utilized for identification of 
genetic expression, see Michael J. Malinowski, Separating Predictive Genetic Testing From 
Snake Oil: Regulation, Liabilities, and Lost Opportunities, 41 JuRJMETRics 23, 31-33, 47 tbl. 1 
(2000) [hereinafter Malinowski, Snake Oil]. See generally Aris Persidis, Biotechnology in a 
Snapshot, 18 NATURE BioTECHNOLOGY IT2 (2000) (Industry Trends Supplement). The tech­
nologies continue to evolve, and often in fundamental ways. For example, in March 2002, 
United States patent 6,355,420 was issued for a new methodology to sequence DNA that 
mimics nature's way of reading genetic information. See Teresa Riordan, Patents: An Ob­
session with DNA and the Human Genome Leads to Development of a Technology, N.Y. TIMES, 
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The pharmaceutical and biotechnology industries are utilizing ge­
netics-based research to improve decision-making and to streamline 
the drug development process, which has given rise to a field 
known as pharmacogenomics.4 In simplest terms, pharmacoge­
nomics is the "study of the impact of genetic characteristics on the 
health care of populations who share the characteristic(s) at issue."5 
Because of this approac h  to drug development, society should antic­
ipate the incremental market introduction of generations of drugs 
with unprecedented genetic specificity and reduced side effects.6 
These drugs will be accompanied by heavy utilization of genetic 
profiling in the delivery of health care.7 Moreover, genetic profiling 
will be used increasingly to improve prescribing traditional 
pharmaceuticals, and even to tailor some pharmaceuticals to accom­
modate the genetic idiosyncrasies of individual patients.8 "The 
study of the impact of genetic characteristics on the health care of 
individuals who possess the characteristic(s) at issue" is a field 
known as pharmacogenetics.9 
Mar. 18, 2002, at C2 (profiling the work of Eugene Chan, founder and chairman of U.S. 
Genomics). 
4 Pharmacogenomics encompasses identifying cell function at the genetic level and using 
predictable cellular response to chemical stimuli at the genetic level to drive drug develop­
ment. See Malinowski, Snake Oil, supra note 3, at 49 tbl.2. This field is likely to accelerate 
drug discovery and introduce some clinical trial cost savings, but it is also likely to divide 
traditional disease classifications and shorten the market lifespan of drugs through the 
more timely introduction of follow-on technology and market substitutes. See Michael J. 
Malinowski, Institutional Conflicts and Responsibilities in an Age of Academic-Industry Alli­
ances, 8 WIDENER L. SYMP. J. 47 n.21 (2001) [hereinafter Malinowski, Institutional Conflicts]; 
Ronald Rosenberg, Development of Drugs Seen Faster, Cheaper, BosTON GLOBE, June 5, 200t 
at Dl-D2, available at 2001 WL 3936608; see also infra Part III.C.2 (arguing that 
pharmacogenetics is producing many challenges that the medical community will have to 
face, such as forcing pharmacists and medical personnel to assume increased responsibili­
ties). But see Arti K. Rai, The Information Revolution Reaches Pharmaceuticals: Balancing Inno­
vation Incentives, Cost, and Access in the Post-Genomics Era, 2001 U. ILL. L. REv. 173, 173 
(2001) (suggesting that cost savings from genomics will generate a market windfall that 
should be used to "scale back" patent protection for pharmaceuticals). 
5 See MalinowskC Snake Oil, supra note 3, at 49 tbl. 2. 
6 See generally id. at 47 tbl. 1. 
7 See Ge11etic Testing in the New Millennium: Advances, Standards, Implications Before the House 
Subcommittee on Technology, 106th Cong., Apr. 21, 1999 (statement of Francis S. Collins); see 
also Malinowski, Snake Oil, supra note 3, at 31-33, 49 tbl. 2; see also Leroy Hood & Lee 
Rowen, Gmes, Genomes, and Society, in GENETIC SECRETS 21 (Mark A. Rothstein ed., 1997). 
8 Malinowski, Snake Oil, supra note 3, at 31-33. 
9 Id. at 49, tbl. 2; see also Sharon Begley, Made-to-Order Medicine, NEWSWEEK, June 25, 2001, at 
65. 
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Utilization of pharmacogenomics and pharmacogenetics raise 
a multitude of law, policy, and market implications. These implica­
tions include: 
1) A shift from decades of dependence on approximately 3,000 
relatively crude pharmaceuticals derived from 483 drug targets for 
the treatment of all human diseases to identification of between 
3,000 and 10,000 drug targets for use in developing potentially tens 
of thousands of drugs;10 
2) Intense demand for human biological samples and access to 
pedigree and family histories;11 
3) Multiplication of the number of clinical trials and increased 
participation in trials;12 
4) More direct communication between human subjects, trial 
sponsors and investigators via Internet compilation and public dis­
semination of clinical trial information;13 
5) Increased commercial pressures on industry and collabora­
tors in academia and medicine and, consequentially, in the absence 
of regulatory reform,14 raised risks to human subjects and research 
integrity;15 
6) Heightened medical privacy concerns as exponentially 
more genetic information will be obtainable from individual 
samples;16 
7) Fracturing of traditional disease classifications and recogni­
tion of health conditions not yet fully identified;17 
8) Increased specificity in FDA drug labeling and restrictions 
on approved uses;1s 
lO See PHARMACEUTICAL INDUSTRY PROFILE 2001: A CENTURY OF PROGRESS 14 (2001) [hereinaf­
ter PhRMA PROFILE 2001], available at www.phrma.org; PhRMA, PHARMACEUTICAL INDUS­
TRY PROFrLE 2000 (2000) [hereinafter PhRMA PROFILE 2000]; Ronald Rosenberg, Data 
Bottleneck Slowing Drug Discovery, BosToN GLOBE, June 20, 2001, at D4; see infra Part II 
("Trends in Pharmaceutical R&D"); see generally ERNST & YoUNG, CoNVERGENCE: THE Bro­
TECHNOLOGY INDUSTRY REPORT {2000). 
11 See infra Part III.A.l ("Access to Human Biological Samples"). 
12 See infra Part III.B ("Metamorphosis of Clinical Research"). 
13 See infra notes 99, 125 and text accompanying notes 124-27. 
14 See infra Part IV ("Proposals for Legislative and Regulatory Reform"); see generally Mali­
nowski, Institutional Conflicts, supra note 4 at 64-73 (introducing proposals for regulatory 
reform). 
15 See infra Part III.A, III.A.l ("Access to Human Biological Samples"), Part III.A.2 ("Protec-
tion of Human Subjects"), and Part III.A.3 ("Conflicts of Interest"). 
16 See infra Part III.A.l ("Access to Human Biological Samples"). 
17 See infra Part III.C.2 ("Health Care Provider Competency"). 
18 See infra note 49 and accompanying text. 
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9) A surge in prescription drug prices and the intensity of cov­
erage/reimbursement challenges resulting from allocation of higher 
research and development ("R&D") costs to smaller patient 
groups;19 
10) Pharmaceutical efforts to reach presently untapped mar­
kets and to introduce preventive drug use t o  offset market losses 
attributable to the fracturing of traditional patient groups (resulting 
from division of tradition disease classifications) and increased pre­
scription precision, which will introduce more new costs such as 
those associated with genetic screening;20 and 
11) Greater public and political support for price controls on 
pharmaceuticals because of a jolting rise in the prices of break­
through new drugs and their delivery. 21 
This article probes select law, policy, and market implications 
of utilization of genetic profiling in drug development and, conse­
quentially, in the delivery of health care. Part I reflects upon tradi­
tional pharmaceuticals and the changing pharmaceutical economy. 
Part II identifies trends in pharmaceutical R&D with a focus on utili­
zation of genetic profiling. Part III probes implications for the deliv­
ery of health care and the roles of patients, research subjects, and 
providers, including pharmacists, and Part IV introduces proposals 
for responsive reforms. 
I. TRADITIONAL PHARMACEUTICALS AND THE CHANGING 
PHARMACEUTICAL EcoNOMY 
After decades of solid profitability, pharmaceutical business 
plans to meet shareholder expectations based upon traditional rates 
19 See infra Part TII.C.3 ("Market Acceptance and Patient Access"). 
20 See Malinowski, Institutional Conflicts, supra note 4, at n.21; Michael J. Malinowski, FDA 
Regulation of Biotechnolog1) Products for Human Use, in 1 ENCYCLOPEDIA OF ETHICAL, LEGAL, 
AND PoLICY IssuEs IN BIOTECHNOLOGY 215, 224 (Thomas J. Murray & Maxwell J. Mehlman 
eds., 2000) [hereinafter Malinowski, FDA Regulation). 
21 This sentiment in favor of price controls on pharmaceuticals was strong enough to prompt 
the National Institute of Health (NIH) to issue a report opposed to introducing additional 
conditions on biomedical research funding. See generally DEP'T HEALTH & H uMA N SERVS., 
NAT'L lNST. OF HEALTH, NIH RESPONSE TO THE CONFERENCE REPORT REQUEST FOR A PLAN 
TO ENSURE TAXPAYERS' INTERESTS ARE PROTECTED (July 2001), available at http:/ /www.nih. 
gov I news/070101 w yden.htm; see also M ilt Freudenheim & Melody Petersen, The Drug­
Price Express Has Run Into a Wall, N.Y. TIMES, Dec. 23, 2001, at 1 (reporting market resis­
tance to expensive new drugs in the absence of significant clinical utility benefits to offset 
price increases). 
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of return have become uncertain if not wholly unrealistic. 22 Many of 
the industry's most profitable pharmaceuticals have gone off patent 
in recent years, and more key patents are approaching expiration.23 
Attempts by members of the pharmaceutical industry to extend 
market control over their products have become fodder for contro­
versy and litigation.24 Moreover, the generic drug industry has 
grown into a large, competitive, and increasingly influential sector, 
especially in an age of intense controversy over drug pricing. 25 
Under the Hatch-Waxman Act,26 generic competitors are able to 
enter the marketplace via an Abbreviated New Drug Application 
("ANDA") by establishing bioequivalence27 with approved prod­
ucts, rather than undertaking the more burdensome task of estab-
22 See Malinowski, FDA Regulation, supra note 20, at 224-25; see B osTON CoNSULTING GRouP, 
THE PHARMACEUTICAL INDUSTRY INTO hs SECOND CENTURY: FROM SERENDIPITY TO STRAT­
EGY 38-39 (1999). But see Virginia Munger Kahn, Managers Say this Decade Belongs to Health 
Care, N.Y. TIMES, Jan. 6, 2002, at 20 (arguing that more biotechnology companies are ex­
pected to post earnings in the next few years and the industry is still i n  a growth phase). 
23 Notable examples of major revenue-generators that have gone off patent in recent years 
include Prilosec, AstraZeneca's drug to treat stomach ulcers, and Prozac, an anti-depres­
sant that generated extraordinary revenues for Eli Lilly. AstraZeneca has attempted to 
cushion its loss by introducing an allegedly improved version of Prilosec, Nexium, and 
Lilly now has a weekly dose version of Prozac. For identification of other pharmaceutical 
products losing patent protection from 2000 through 2003, including expiration date and 
sales information, see RoBBINS-ROTH, supra note 2, at 164-165 tbl. 20.1. 
24 For example, in December 2001, 29 attorneys general filed suit against Bristol-Myers 
Squibb to release the company's market hold over Buspar, an anti-anxiety drug, so that 
generic drugs could enter the market. See Kahn, supra note 22, at 20. Prior to this action, 
the Federal Trade Commission, U.S. Attorney's Office in Boston, consumer coalition 
groups, and class action lawyers (including attorney veterans of the tobacco wars) filed 
various separate lawsuits against pharmaceutical makers. These suits were based upon 
allegations that the companies inflated drug prices, and often claimed that the defendants 
had been blocking the market introduction of generic versions of their medications. See 
Michael J. Malinowski, Health and Human Services, in DEVELOPMENTS IN ADMINISTRATIVE 
LAw AND REGULATORY PRACTICE 2000-2001 391-392 Oeffrey S. Lubbers ed., ABA 2002). 
25 See Generic Pharmaceutical Association (GPhA), at www.gphaonline.org (noting that 
while brand name prescription drugs represented 55% of all prescriptions, they consumed 
more than 90% o f  drug therapy dollars spent at retail). 
26 Drug Price Competition and Patent Restoration Act of 1984 ("Hatch-Waxman Act"), Pub. 
L. No. 98-417, 98 Stat. 1585 (codified in scattered sections of 15 U.S.C., 21 U.S.C., 28 U.S.C., 
and 35 U.S.C.). See generally John Hudson, Generic Take-Up in the Pharmaceutical Market 
Following Patent Expiration: A Multi-Country Study, 20 lNT'L REv. L. & EcoN. 205, 211 
(2000). 
27 "Bioequivalence" means equivalence in the amount of active drug that a product provides 
to the site of drug action. For more information, visit the FDA web site at www.fda.gov I 
cder /handbook/bioequiv.htrn. 
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lishing fundamental safety and efficacy.28 Generic manufacturers 
thereby have the opportunity to enter the market without incurring 
hundreds of millions of dollars in R&D costs-for example, the 
costs associated with generating and processing often voluminous 
clinical data from Phase I through Phase III trials to establish safety 
and efficacy for market approval, and then follow-on studies 
("Phase IV data")-and without assuming the enormous risks, costs, 
and time-consuming market development challenges undertaken by 
drug innovators.29 
Moreover, in spite of law reforms in favor of globalization of 
life science markets such as enactment and implementation of the 
General Agreement on Tariffs and Trade ("GATT") and Trade Re­
lated Intellectual Property Sections ("TRIPS"),30 longstanding seams 
among these global markets continue to unravel. Although the 
United States may remain optimistic about the promise of fully im­
plementing GAIT /TRIPS by 2015, even among signatories with de­
veloping economies, daunting challenges to global harmonization 
continue to arise.31 GATT /TRIPS is being implemented in the con­
text of increasing disparity in life science capabilities among devel­
oped and developing economies, which is all the more difficult to 
ignore in an age of unprecedented global communication, interna­
tional travel, and shared, increasingly ominous epidemiological 
challenges. The burgeoning biotech sectors of the United States and 
Europe and the market availability of drugs such as Herceptin for 
28 According to the Pharmaceutical Research and Manufacturers of America ("PhRMA"), the 
amount of pharmaceutical sales allocated to R&D will have reached 18.5 percent in 2001 
(compared with 17.4 percent in 1999), meaning that in 2001 the industry spent $26.3 billion 
on R&D. See PhRMA PROFILE 2001, supra note 10, at ch. 2. According to PhRMA, the time 
from synthesis of a new drug to market approval has stretched to 14.2 years in the 1990s. 
Id. (relying upon data from the Tufts Center for Drug Development). For details regard­
ing the FDA's requirements to establish safety and efficacy for a range of products, see 
www.fda.gov. 
29 See supra note 28. See also MICHAEL J. MALINOWSKI, BIOTECHNOLOGY LAw, BusiNEss, & 
REGULATION ch. 11 (Aspen Law & Business 1999 & Supps. 2001, 2002) (describing the con­
tent of the phases). 
30 Agreement on Trade Related Aspects of Intellectual Property Rights, Apr. 15, 1994, Mar­
rakesh Agreement Establishing the World Trade Organization, Annex 1C, Legal Instru­
ments-Results of  the Uruguay Round, val. 31, 33 I.LM. 81, 84 (1994) (expressing a desire 
to reduce obstacles to international trade through protection of intellectual property 
rights). 
31 See generally Calestous Juma et al., Global Governance of Technologt;: Meeti11g the Needs of 
Developing Countries, 22 INT. J. TECH. McMT. 629, 646 (2001); Jeffrey D. Sachs, Balms for the 
Poor, THE EcoNOMIST, Aug. 14, 1999, at 63. 
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an aggressive form of breast cancer,32 Cerezyme for Gaucher's dis­
ease,33 Pulmozyme for cystic fibrosis,34 and protease inhibitors for 
AIDS patients35 are juxtaposed with the proliferation of deaths in 
developing economies from highly preventable and treatable condi­
tions such as basic nutritional deficiencies36 and malaria.37 Public 
health and delivery of care inadequacies in countries such as the 
Russian Republic, other former members of the Soviet Union, and 
China are causing once treatable conditions such as tuberculosis to 
take new, virulent and generally ominous forms.38 Even in the 
shadow of impending GATT /TRIPS implementation, the wildfire 
spread of  AIDS and associated deaths in African nations has re­
newed demands for compulsory licensing of pharmaceutical-owned 
32 Information about Herceptin is available at www.herceptin.com. Herceptin generally is 
administered in combination with Taxol, and the total cost of this cocktail is approxi­
mately $12,000 per patient for a six-month course ($6,000 per drug). See Beezy Marsh, The 
Miracle Cocktail: New Drugs Cocktail Can Help Women to Live Longer, DAILY MAlL, May 16, 
200t available at 2001 WL 21128992. 
33 The world's most expensive medicine, Cerezyme, costs approximately $175,000 per pa­
tient annually. See Dan Gerstenfeld, Teva to Market Treatment for Gaucher's Disease, THE 
}ERUSALEM PosT, Nov. 21, 2001, available at 2001 WL 6617162. 
34 Information about Pulmozyme may be obtained from its manufacturer, Genentech, Inc. of 
South San Francisco, at www.gene.com. See J.D. Kleinke, The Price of Progress: Prescription 
Drugs in the Health Care Market, HEALTH AFF. 4360, Sept. 1, 2001, available at 2001 WL 
10696964 (including Pulmozyrne in a category of expensive new drugs that lower short­
term health care costs but guarantee higher costs in the long run-"the economics of 
smoking in reverse"). 
35 A year's therapy in the United States costs approximately $8,000. See Latest Developments 
in HIV Diagnosis and Treatment, PuLSE 60, Feb. 11, 2002, available at 2002 WL 13571781. 
::16 Genetic modification, though opposed by many in developed economies, could prove a 
cost effective means to overcome some of these public health challenges. For example, 
golden rice is a genetically modified strain of rice designed to overcome debilitating vita­
min A deficiency. See David Lague, Biotechnology, FAR. E. EcoN. REv. 34, Apr. 4, 2002, 
available at 2002 WL-FEER 5169787. 
37 "Of a total $70 billion spent on health care research worldwide in 1998, for instance, only 
$100 million was set aside for malaria research (about a tenth of the cost of the U.S. De­
partment of Defense's recent 'experiment' of intercepting a ballistic missile with a ground­
launched exo-atrnospheric kill vehicle)." Rights of Access, 19 NATURE BIOTECHNOLOGY 693 
(Aug. 2001). Although highly treatable and preventable with contemporary therapeutics, 
malaria remains pervasive in developing economies and, with AIDS and tuberculosis, has 
become an international public health priority and the subject of a multibillion-dollar 
global fundraising initiative-'The Global Fund to Fight AIDS, Tuberculosis, and Mala­
ria," which is a private foundation. See Christopher Newton, HH Secy. Thompson to Visit 
Africa, AssociATED PRESS, Mar. 29, 2002, available at 2002 WL 17189950; Bill Gates, Bono Call 
on Leaders at World Economic Forum, M2 PRESSWIRE, Feb. 1, 2002, available at 2002 WL 
4158486. 
38 
''Tuberculosis is turning out to be one of the major killers of the new millennium and is 
probably the most serious threat to public health after AIDS." TB Continues t o  be Scourge of 
the Century, THE TIMES oF INDIA, Mar. 27, 2002, available at 2002 WL 17725854. 
38 Hous. J. HEALTH L. & PoL'Y 
intellectual property and inspired the government of South Africa, 
with the implied support of the World Trade Organization, to 
trump patent rights with public health overrides.39 The leading 
AIDS drug manufacturers within the pharmaceutical industry have 
made major concessions but have been unable to completely fend 
off generic competitors.4° Consequentially, these nations have reaf­
firmed the pharmaceutical industry's apprehensions about interact­
ing with the governments of developing economies and widened 
the life science gap yet further, thereby ensuring future disputes 
over access to innovative pharmaceuticals and tensions over recog­
nition of intellectual property rights. 41 The absence of meaningful 
life science capabilities in many biologically diverse areas of the 
world raises global susceptibility to public h ealth challenges.42 
The pharmaceutical industry is responding to this plethora of 
challenges by changing its methodologies and dramatically increas­
ing the percentage of revenue allocated to R&D.43 The overall reve­
nue allocated to R&D has risen from 11 °/o to 18.5°/o over the last 
twenty years,44 and overall pharmaceutical investment in R&D has 
risen from approximately $2 billion in 1991 to $30.5 billion in 2001.45 
Nevertheless, the pharmaceutical sector's aggressive embrace 
of the precision in drug development introduced through biotech­
nology and fields such as pharmacogenomics will have market con­
sequences for these multinational pharmaceutical behemoths whose 
existence is premised upon voluminous market scale and products 
39 Juma et al., supra note 31, at 630; Donald G. McNeil Jr., New List of Safe AIDS Drugs, N.Y. 
TIMES, Mar. 21, 2002, at A3 ("In a move that could help bring down the price of AIDS 
medicines for poor countries, the World Health Organization today released its first list of 
manufacturers for safe AIDS drugs, which included a Jarge Indian producer of generics 
and three smaller European ones."). 
40 See McNeil, supra note 39, at A3. 
41 Cf. Juma et al., supra note 31, at 630; McNeil, supra note 39, at A3. For those who have not 
participated directly in dispute resolution with African nations over this issue or accessed 
full information about those deliberations, it would be presumptuous to declare that more 
satisfactory, workable alternatives to this outcome were overlooked. Therefore, it must be 
acknowledged that alleviating ongoing human suffering and death attributable t o  AIDS in 
developing economies and u ndertaking measures to contain the accompanying threat to 
global public health at the present time by forcing industry concessions may justify esca­
lating the longer-term challenge of closing the life science technology gap between devel­
oped and developing economies. 
42 See generally LAURIE GARRETT, THE CoMING PLAGUE (1994); JuDITH MILLER, STEPHEN ENGEL-
BERG, WILLIAM BROAD, GERMS: BIOLOGICAL WEAPONS AND AMERICA'S SECRET WAR (2001). 
43 See supra note 28; see also Malinowski, Institutional Conflicts, supra note 4, at 48-49. 
44 See PhRMA PROFILE 2001, supra note 10, at ch. 2. 
45 See id. 
MALINOWSKI 39 
that generate billion-dollar revenue streams on an annual basis.46 
As addressed below, decades of extraordinary profitability from 
broad market exploitation, including extensive off-label use by phy­
sicians, of pharmaceuticals developed from several hundred drug 
targets to treat all human diseases is the past, not the future, of com­
mercial life science. 47 
II. TRENDS IN PHARMACEUTICAL R&D 
Traditional pharmaceuticals are understood largely based 
upon use in human subjects and patients-meaning clinical trials 
and physician experiences that indicate which compounds alleviate 
and/ or ameliorate symptoms associated with particular diseases.48 
There is  wide variation in patient responsiveness for most 
pharmaceuticals, ranging from non-responsiveness to severe ad­
verse events from the standard of care dosage. Consequentially: 
1) Physicians have practiced broad off-label discretion, mov­
ing use of most pharmaceuticals well beyond the clinical trial design 
for safety and efficacy and resulting FDA labeling;49 
2) Our aging population now is testing the limit of our knowl­
edge about drug combinations and interactions;50 
3) Dosage and drug combinations raise patient-by-patient 
challenges for physicians;51 
4) Estimates for the health care costs associated with unin­
tended reactions to pharmaceuticals have reached as much as $100 
billion annually;52 and 
46 See Malinowski, FDA Regulation, supra note 20 at 224; Malinowski, Institutional Conflicts, 
supra note 4, at n.21. See generally BosTON CoNSULTING GROUP, supra note 22, Chapter 3, 
app.2. 
47 See infra notes 151-154 and accompanying text. 
48 See generally BosTON CoNSULTING GROUP, supra note 22, app.2; PhRMA PROFILE 2001, supra 
note 10, ch. 3. 
49 Companies Balance Risks, Rewards of Off-Labeling, FooD & DRUG LETTER, Mar. 15, 2002, 2002 
WL 12321164 . 
50 Mary Desmond Pinkowish, Prescribing for Older Patients: 5 Points to Remember, PATIENT 
C.to.RE 45, available at 2000 WL 100711936 (Aug. 15, 2000). 
51 Id. 
52 Althou gh the reliability of the Institute of Medicine's 1999 report has been called into 
question (available at www.IOM.edu), it is beyond dispute that medical mistakes are re­
sponsible for thousands of deaths per year. See Death Total from Medical Mistakes is a Matter 
of Dispute, INDIANAPOLIS NEws/INDIANAPOLIS STAR, Mar. 31, 2002, at J01, available at 2002 
WL 16980099; see also David Brown, The End of an Error? Big Business, Launching a New Era 
of Reform, is Pressuring Hospitals to Cut Mistakes, WASH. PosT, Mar. 26, 2002, at FOl, available 
at 2002 WL 17585639. The problem is also pervasive outside of the United States. See 
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5) Many prevalent diseases remain untreatable with tradi­
tional pharmaceuticals.53 
However, times are changing. Through fields such as ge­
nomics (identifying genes and gene function),54 proteomics (identi­
fying protein function),55 and bioinformatics (the combination of 
biotechnology and information technology),56 the pharmaceutical 
industry anticipates churning vast amounts of data from volumi­
nous numbers of samples and identifying as many as ten thousand 
drug targets over the next several years.57 This expectation is pre­
mised upon new sets of tools for discovering, mapping, and modi­
fying genetic information-meaning tools for distinguishing gene 
expression and isolating which particular genes to study.58 Utiliza­
tion of DNA chips, which are silicon chips embedded with multiple, 
distinguishable bits of DNA, has made large-scale screening possi­
ble.59 DNA chips can be used to test the samples of individuals for 
Sarah Lyall, More Deaths In England Due to Error, Report Says, N.Y. TIMES, Dec. 20, 2001, at 
A6 (reporting that approximately 1,200 people died in public hospitals in Britain last year 
due to mistakes in prescribing and administering medications). 
53 Harnessing Genes, Recasting Flesh, THE PHARMACEUTICAL CENTURY, available at http:/ /pubs. 
acs.org/joumals/pharmcent/Ch8.htrnl. In spite of the resources invested over the past 
several decades to combat diseases responsible for the h ighest levels of mortality in the 
United States, namely heart disease and cancer, those diseases remain formidable chal­
lenges. As of March 2001, heart disease was responsible for 35% of all deaths among those 
65 and older, and cancer was responsible for 22% of the deaths in this age group. CTRS. 
FOR DISEASE CONTROL AND PREVENTION, NAT. CNTR FOR HEALTH STATISTICS, TRENDS IN 
CAUSES OF DEATH AMONG THE ELDERLY available at www.cdc.gov/nchs/data/aging 
trends I 0 I death. pdf.  
54 Malinowski, Snake Oil, supra note 3, at tbl. 1. 
55 Id. at tbl. 2. IBM's Blue Gene can crack the genetic code for proteins from start to end. Eric 
Stawiski, The Biologist Meets the Computer Scientist, WoRLD & I, Mar. 1, 2002, p. 137143, 
available at 2002 WL 9015548. For an illustration of how IBM is using its supercomputing 
technology for biomedical research, see IBM/Physiome Sign Supercomputing/Biological Model­
ing Pact, MAINFRAME CoMPUTING (Oct. 1, 2001), available at 2001 WL 12586424. 
56 Malinowski, Snake Oil, supra note 3, at tbl. 1. 
57 See supra note 10 and accompanying text. As stated earlier, the approximately 3,000 tradi­
tional pharmaceuticals on the market have been developed from just 483 drug targets. 
PhRMA, INDUSTRY PROFILE 2001, supra note 10, at v. 
58 See generally Malinowski, Snake Oil, supra note 3 at 31-33; PhRMA, INDUSTRY PROFILE 2001, 
supra note 10 at ch.9; see BosTON CoNSULTING GRoUP, supra note 22, at 53-55, app.l. 
59 The basic methodology is to use the process of hybridization (predictable nucleotide bond­
ing between A&T, C&G) and probes-short nucleotide chains that have a signaling en­
zyme that glows when the probe hybridizes (i.e., the gene of interest is present)-to isolate 
and identify instances of genetic expression. RoBBINs-RoTH, supra note 2, at 73-74. Today, 
scientists are able to access commercial DNA chips with the capacity to screen for more 
than 6,000 specific genetic sequences (DNA arrays). Malinowski, Snake Oil, supra note 3, at 
32. Affymetrix has introduced a commercial chip with the capacity to screen for 400,000+ 
arrays by 2003 (a 1999 prediction that may already have been realized). See RoBBINs-RoTH, 
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the p resence of thousands of identified genetic variations and, alter­
natively, to screen hundreds of thousands of individuals with a 
shared phenotype characteristic to isolate and identify shared ge­
netic expression. This technology has made it feasible to do com­
prehensive gene expression comparisons among large groups of 
people-e.g., a well-documented disease group such as the 
Framingham heart study patients, or even the population of Ice­
land.60 In fact, bioinformatics capabilities have inspired the forma­
tion of a consortium among pharmaceutical, biotech, and academic 
participants to compile data on the impact of variations of single 
nucleotide polymorphisms (SNPs), meaning single letters in the 
DNA blueprint-a denine ("A"), cytosine ("C"), guanine ("G"), or 
thytosine ("T")-on susceptibilities to diseases and responsiveness 
to prescription drugs and/ or drug combinations.61 
One consequence of this approach to pharmaceutical R&D is 
unp recedented p re cision. Reflective of this trend, those engaged in 
contemp orary life science R&D have b een filing a deluge of patent 
app lications.62 More profound from a human health perspective, in­
dustry application is closely trailing the advancement of contempo­
rary life science and, in turn, industry is financing and adv ancing 
this field of science-thereby moving us into an era of genetic preci­
sion in pharmaceutical development and prescription drug deliv-
supra note 2, at 73-81; see also David Stipp, Gene Chip Breakthrough Microprocessors Have 
Reshaped our Economy, Spawned Vast Fortunes and Changed the Way We Live. Gene Chips 
Could be Even Bigger, FoRTUNE, March 31, 1997, at 56. 
60 See infra notes 115 and 148. 
61 See Orchid Biosciences, Inc., at http:/ /www.orchid.com. Consider that, if each nucleotide 
base letter in y o ur DNA blueprint was the size of a letter in standard typewritten text, 
your DNA blueprint would be a sentence spanning from Portland, Oregon to Chicago, 
Illinois. A SNP is just one of those billions of letters. Tom Abate, The Gene Age/Inside Our­
selves/Two Groups on Verge of Reading the Entire Human Gene Code, S. F. CHRON., Apr. 25, 
2000, at Al. 
62 See Michael J. Malinowski, The Commodity of Intellectual Property in the Risky Business of Life 
Science, 41 JuruMETRics 414 & nn. 33-34 (1999) (book review essay). The PTO now issues 
70% more patents-approximately 170,000 in 1999-than it did a decade ago. See UNITED 
STATES PATENT & TRADEMARK OFFICE, Annual Reports: 1999 Annual Report, available at 
http:/ /www.uspto.gov /web/offices/corn/annual/index.html; see also Peter Coy, The 21st 
Century Corporation, Bus. WEEK, Aug. 28, 2000, at 78. Patent applications for biotechnol­
ogy, organic chemistry, and pharmaceuticals have nearly doubled from 1996 to 2000 
(reaching 32,705 in 2000), and approximately two-thirds of the 2000 a pplications were for 
genomics patents. See UNITED STATES PATENT & TRADEMARK OFFICE, Annual Reports: 2000 
Annual Report, available at http: 11 www. uspto.gov I web I offices I com/ annual/ index.html. 
The PTO has added 800 examiners and estimates a 25% increase in filings for 2001. 
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ery.63 Consequentially, genetic testing is entering the medical 
setting as an accompaniment to drug delivery.64 For example, in 
1998, Genentech, Inc. (South San Francisco, CA) introduced Hercep­
tin into the marketplace for women with an aggressive form of 
breast cancer who also have over-expression of Her-2 neu; the mar­
ket entry of Herceptin was accompanied by the commercial availa­
bility of a test to screen for over-expression of Her-2 neu.65 In 
January 2000, Visible Genetics Inc. (Toronto, CA) received national 
coverage approval from France for a genotyping kit for HIV that 
assists doctors in making the best use of available medicines.66 In 
2002, the FDA approved the test for the U.S. market.67 In addition, 
Virologic (South San Francisco, CA) is  manufacturing a homebrew 
version of this test, which enables patients and their physicians to 
determine whether they are infected with drug-resistant strains of 
HIV.68 
The research community, medical community, and even the 
general public should anticipate access to more pharmacogenomic 
testing capabilities in the foreseeable future. 69 In fact, companies 
such as Orchid Pharmaceuticals (NJ), Pangea Systems, Inc. (Oak­
land, CA), and HySeq Inc (Sunnyvale, CA) have announced inten­
tions to make information about genes available over the Internet 
for researchers first, and ultimately for consumers.70 Prior to his de­
parture from Celera, Inc.,71 the company that challenged the U.S. 
63 See generally Malinowski, Snake Oil, supra note 3, a t  26; PhRMA PROFILE 2001, supra note 10 
at ch.2; PhRMA PROFI LE 2000, supra note 10 at ch. 2. 
6.J See generally Malinowski, Snake Oil, supra note 3. 
65 See ge11erally RoBERT BAZELL, HER-2: THE MAKING OF HERCEPTJN, A REVOLUTIONARY Tr{EAT­
MENT FOR BREAST CANCER 175-186 (1998); see also FDA Approves DAKO Herceptest to Identify 
Potential Patients for Herceptin, the New Breast Cancer Treatment Drug from Genentech, Bus. 
WIRE 20:26:00 (Sept. 25, 1998). 
66 See Andrew Pollack, When Gene Sequencing Becomes a Fact of Life, N.Y. TIMES, Jan. 17, 2001, 
at C1; see also Malinowski, Snake Oil, supra note 3, at 31 n.31. 
67 See Visible Genetics Inc., FDA Grants Market Clearance of HlV Genotyping System, BrolNDEX, 
(Apr. 10, 2002), available at 2002 WL 18689534; see also Tom Abate, The Economics of Genetic 
Testing/The Race to Develop New Ways to Detect Disease is As Much About Cost as it is About 
Technology, S.F. CHRON., Feb. 10, 2002, at G1, at 2002 WL 4012496 (detailing information on 
the strengths and weaknesses of Celera). 
68 See id. 
6q See generally Malinowski, Snake Oil, supra note 3, at 32-33. 
70 See id. 
71 David Shook, Celera: A Biotech That Needs a Boost: The Onetime Genomics Highflier has to 
Replace Departed Founder Craig Venter and Ramp Up Its Drug Development Unit, Bus. WEEK, 
Mar. 1, 2002, available at 2002 WL5145033. 
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government-headed initiative in a race to map the human genome,72 
founder Craig Venter stated that the ultimate Celera consumer 
would be the individual who will access the company's databases to 
get information about him or herself and make more informed 
health care decisions.73 Some companies already have moved for­
ward with business plans premised upon genetic profiling and di­
rect-to-consumer interaction. For example, in the Summer of 2000, 
DNA Sciences launched a Web site to recruit people to donate their 
DNA to help identify genetic variations that cause disease, thereby 
compiling a database gene trust, a large statistical sample.74 In De­
cember 2000, DNA Sciences acquired PPGx, which had announced 
plans in the Fall of 2001 to offer a genetic test, the 2D6 test, directly 
to the public .75 The 2D6 test identifies the approximately ten per­
cent of the population who are poor metabolizers of a broad array of 
prescription drugs_76 
III. IMPLICATIONS FOR THE DELIVERY OF HEALTH CARE AND 
THE RoLES OF PATIENTS, REsEARCH SuBJECTS, 
AND PROVIDERS 
The shift from decades of dependence on pharmaceuticals 
crude by contemporary standards to generations of pharmaceuticals 
developed from potentially ten thousand plus drug targets77 will 
prove an impetus for ongoing changes in life science methodology. 
Genetic precision in drug development also will impact the prac­
tices and roles of commercial sponsors, research subjects, patients, 
and health care providers . 
A. Basic Life Science R&D Implications 
As stated above, in contemporary biomedical science, increas­
ingly, less means more. Scientists have long appreciated that all di-
72 See supra note 1 .  
73 Lawrence M. Fisher, Surfing the Human Genome: Data Bases of Genetic Code Are Moving to the 
Web, N.Y. TIMES, Sept. 20, 1999, at  C1. Subsequently, Venter has moved on to found two 
institutes. See Nicholas Wade, Thrown Aside, Genome Pioneer Plots a Rebound, N.Y. TIMES, 
Apr. 30, 2002, at 01, D6. 
74 DNA Sciences, at http: /  /www.dna.com. 
75 DNA Sciences Inc., MEo Ao NEws, Aug. 1, 2001, at 16, available at 2001 WL 26968874. 
76 David Stipp, A DNA Tragedy, FoRTUNE, Oct. 30, 2000, at 170, available at 2000 WL 24218519; 
Cinda Becker, Special Report: The DNA Rx, MoDERN HEALTHCARE, Aug. 28, 2000, at 24, 
available at 2000 WL 8169272. 
77 See supra note 10 and accompanying text. 
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versity within the human species is attributable to a mere . 1  percent 
of DNA.7B However, in March 2001, the science community deter­
mined that the human genome consists of approximately thirty 
thousand genes rather than the eighty to one hundred fifty thou­
sand genes estimated throughout most of the 1990s.79 Presumably, 
individual genes do much more than anticipated before this count 
adjustment, meaning that gene function is a more intricate and com­
plicated series of processes than previously appreciated. 
The resulting reduction in scale and heightened intricacy in life 
science suggests that patenting at the level of expressed sequence 
tags ("ESTs") and single nucleotide polymorphisms ("SNPs") is 
likely to increase even in the face of higher USPTO standards for 
utility and written disclosure.80 Other readily apparent implications 
of this heightened intricacy in life science R&D and utilization of 
bioinformatics include raised demand for human biological samples 
and access to pedigree information and family histories,81 intensi­
fied commercial pressures on both industry and academia in an age 
of academic-industry collaborations and increasingly pervasive con­
flicts of interest that threaten the safety of research subjects and the 
integrity of data, 82 continued multiplication in the number of clinical 
trials initiated and more demand for trial subjects,83 and more direct 
communication between research sponsors and potential research 
participants to access both samples and subjects.84 
1 .  Access to Human Bio logical Samples 
Many tracks of drug development research, including research 
u tilizing pharma cogenomics, are dependent upon access to vast 
78 See www.arrmh.org/ exhibitions/ genomics; see also Francis S. Collins et al.,  New Goals for 
the U.S. Human Genome Project: 1998-2003, 282 SciENCE 682, 683 (1998). 
79 Gene Weingarten, Genetic Leftovers: Those Extra DNA Strings May Hold Keys to Oddities, 
Hous. CHRON., Mar. 23, 2001, at 1, available at 2001 WL 3007837. 
110 ln January 2001, the agency announced new "Utility Examination Guidelines" and "Writ­
ten Description Guidelines'' intended to make it more difficult to patent genes. See Utility 
Examination Guidelines, 66 Fed. Reg. 1092-1099, 1097-99 (Jan. 5, 2001) (setting forth spe­
cific standards); Guidelines for Examination of Patent Applications Under the 35 U.S.C. 
§ 112, P1, "Written Description" Requirement, 66 Fed. Reg. 1099 (2001). These guidelines 
clarify that a claimed invention must have a specific and substantial utility that is credible 
or a readily apparent, well-established utility. See 66 Fed. Reg. at 1092-1099 (2001). 
til See i11jra section III.A .1. 
82 See infra sections III.A.2., III.A.3. 
1n See infra section III.B. 
84 See i11jra notes 99, 125 and accompanying text (identifying web sites that make clinical trial 
information directly accessible by the general public). 
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numbers of hutnan subject samples and the resulting data.85 In fact, 
as discussed in Part II, ongoing scientific and commercial enthusi­
asm at the forefront of life science now centers on technical capabili­
ties-microarrays, DNA chips, and other enabling technologies­
that exponentially increase the number of human biological samples 
that can be run and the amount of data that can be generated and 
processed.86 The capability to run many thousands of genetic com­
parisons in the matter of minutes has jolted scientific and commer­
cial detnand to access and compile large-scale population 
databases.87 
The disconnect between the Clinton Administration and the 
Bush Administration has left unanswered many framed, highly con­
troversial life science and health care policy and regulatory ques­
tions that may linger for years in spite of the intensity of the 
ongoing genetics revolution. One such question is whether the 
Common Rule88 will be expanded to encompass all human subject 
research, perhaps based upon the Commerce Clause, 89 rather than 
just federally funded research.9o Another is whether "human sub­
jects research" will be interpreted to include samples encrypted but 
ultimately identifiable.91 
85 See generally supra notes 54-61 and accompanying text (discussing trends in R&D that re­
flect these demands). 
86 See id. 
87 See id. 
&! The Department of Health and Human Services' policy to protect human subjects, known 
as the Common Rule, is codified at 45 C.F.R § 46 (2000). For a technical discussion about 
human subject protection regulations and their implementation, see MICHAEL J. MALINOW­
SKI, BIOTECHNOLOGY: LAW, BUSINESS, & REGULATION § 9.02 (Aspen Law & Business 1999 & 
Supps. 2001, 2002); see generally PrucEWATERHOUSE CooPERS, LLP, INSTITUTIONAL REFER­
ENCE BoARD (IRB) REFERENCE BooK (Michele K Russell-Einhom & Thomas Puglisi, eds., 
2001). 
R9 U.S. CoNsT. art. 1 ,  § 8, cl.3. 
90 See NATIONAL BroETHrcs ADvisORY CoMMISSION, RECOMMENDATIONS: En-neAL AND Poucv 
IssuEs IN RESEARCH INVOLVING HuMAN PARTICIPANTS (May 18, 2001) [hereinafter NBAC 
Recomrnendations]  (proposing the establishment of one single, independent federal office to 
implement a unified, single set of regulations and guidance), available at http:/ /bioethics. 
georgetown.edu/NBAC/pubs.html; see also Ethical and Polietj Issues in International Re­
search: Clinical Trials in Developing Countries (Apr. 18, 2001) (addressing whether U.S. re�­
lations remain appropriate in the context of international research and the changmg 
landscape of international research due to pressures on private companies to become more 
efficient in the conduct of research), available at http:/ /bioethics.gov I clinical/ ·  
91 See NBAC Recommendations, supra note 90. The primary regulatory issue is whether en­
crypted human biological samples will be treated as the equivalent of identifia�le .sa�ples 
and therefore be fully subjected to the requirements of informed consent and mstituho�al 
review board (IRB) oversight. See 45 C.P.R. § 46.101 (2000) (referring to DHHS' protection 
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During the Clinton Administration, the anticipated expansion 
and meaningful enforcement of human subject protection regula­
tions and debate over the implementation of the Health Insurance 
Portability and Accountability Act ("HIP AA")92 raised the commer­
cial viability of companies in the business of providing an "ethically 
sound" alternative to the vast human biological material reposito­
ries compiled over the last several decades.93 However, in March 
2002, the Bush Administration discarded the HIP AA informed con­
sent requirement as "unworkable," thereby alleviating some imme­
diate angst in the health care delivery and life science 
communities.94 Nevertheless, given the timeline for developing a 
pharmaceutical,95 there now is regulatory pressure on those en­
gaged in life science R&D to either use wholly unidentifiable sam­
ples or to introduce significant complexity and expense-e. g., 
purchase the services of commercial suppliers of human biological 
materials-which presumably will be folded into escalating drug 
costs. In the absence of implementation and enforcement of reliable 
regulatory safeguards around sample collection and use that ensure 
for human subject regulations); 21 C.F.R. 50.20 (2001 )  (referring to FDA informed consent 
regulations). See also DEP'T OF HEALTH & HuMAN SERVS ., OFFICE FOR HUMAN RESEARCH 
PROTECTfONS, COMPLIANCE OVERSIGHT PROCEDURES (2000), at http:/ /www.ohrp.osophs. 
dhhs.gov I compovr.htm. 
42 HHS Proposes Changes that Protect Privacy, Access to Care; Revisions Ensure Privacy Protec­
tions, Removing Obstacles to Care, U.S. NEWSWIRE, Mar. 21, 2002, 2002 WL 4575666 [hereinaf­
ter HHS Proposes Changes] .  
93 Examples of these commercial suppliers include The First Genetic Trust, available at  www. 
firstgenetic.net, and Genomics Collaborative, Inc., available at www.dnarepository.com. 
See Jeffrey Krasner, Gene Pooling: Company Builds World's Largest Library of Genetic Material, 
BosTON GLOBE, Aug. 22, 2001 ,  at Fl. Many of the hundreds of millions of samples held in 
preexisting repositories were collected during the course of  routine diagnostic and medi­
cal procedures under a theory of medical waste and donor abandonment and without 
meaningful consent. Eric Niiler, Surgical Refuse is Research Treasure, THE S.D. UNION-Tl{IB­
UNE, Dec. 6, 2000, at Fl.  In addition to commercial suppliers, some teaching hospitals are 
compiling central tissue banks with contemporary informed consent practices to become 
future suppliers. See Jeffrey Krasner, Partners HealthCare Planning Tissue Bank: Hospital 
Group Cites Research Potential, BOSTON GLOBE, Sept. 4, 2001, at Dl. 
94 See HHS Proposes Changes, supra note 92. Subsequently, the Bush administration changed 
the burden for collecting written informed consent to notice of privacy policies. See Jen­
nifer Kulynych & David Korn, Use and Disclosure of Health Information in Genetic Research: 
Weighing the Impact of the New Federal Medical Privacy Rule, 28 AM. J.L. & MEo. 309, 322-23 
(discussing the ramifications of the proposed rule changes); see also 45 C.F.R. § 164.508 
(2002) (reflecting that these policy changes become effective on Oct. 15, 2002). 
9:; See supra note 28 (PhRMA estimates that, during the 1990s, the time required to develop a 
new drug stretched to more than 14 years). 
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accountability to sample donors,96 the ability to generate exponen­
tially more genetic information from a given sample will affirm and 
heighten medical privacy concerns.97 
2 .  Protection of Human Subjects 
Meaningful pharmacogenomics research is expensive, a s  are 
human clinical trials. 98 Even if pharmacogenomics can streamline 
trials, today, many more trials need financing.99 The pressure from 
shareholders to generate favorable data and to introduce break­
through drugs to offset the loss of billion-dollar revenues due to 
patent expirations has heightened over the last few years, and the 
pressure continues to rise .100 
The United States' framework to protect human subjects and 
complementary agency policies and enforcement practices101 gener-
96 Implementation of the HIPAA regulations will increase medical privacy protections but, at 
this time, whether these protections will offset the increased flow of genetic information 
remains an open question, especially since the Bush Administration has discarded the in­
formed consent provision. See supra note 94. 
97 See generally Chris Meyers et al., Genomics: Implications for Health Systems/ The Ef ect of Ge­
nomics on Health Services Management: Ethical and Legal Perspectives, 1 7  FRONTIERS oF 
HEALTH SERV.S MGMT. 316 (2001). 
98 See Malinowski, Institutional Conflicts, supra note 4, at  n.94 (noting physicians may be paid 
reimbursement fees of thousands of dollars per patient). The "American Association of 
Health Plans generally encourages reimbursement for the routine costs of care associated 
with NIH-sponsored trials, and several large private health plans have been routinely cov­
ering cancer research trials conducted by the National Cancer Institute." Id. at 55; see gen­
erally Francis H .  Miller, Trusting Doctors: Tricky Business When It Comes to Clinical Research, 
81 B.U. L. REv. 423, 425 (2001) (stating that "some drug and device manufacturers now 
compensate primary care physicians for enrolling their patients in clinical studies"). 
99 See Malinowski, Institutional Conflicts, supra note 4, at n.l and accompanying text. To learn 
what is transpiring in the clinical trial segment of the drug development pipeline, see 
http: / I clinicaltrials.gov (detailing approximately 5,500 mostly government-funded 
clinical trials); http: I I cancer. gov j clinical_ trials (exhibiting the N a tiona! Cancer Institute' 5 
clinical trial listing); http:/ j actis.org (the AIDS Clinical Trials Information Service (AC­
TIS)); http : /  /www.veritasmedicine.com (listing trials and standard treatments for numer­
ous diseases); http : /  /www.americasdoctor.com/clintrials/main.cfm (showcasing trials in 
seven disease categories, excluding cancer); and http:/ /www.acurian.com/patient (devel­
oping lists of trials i n  various disease categories) . 
100 See Steven R. Salbu, Regulation of Drug Treatments for HN and AIDS: A Contractarian Model 
of Access, 1 1  YALE J. ON REG. 401, 442-43 (1994) (describing the need for private experimen­
tal drug companies to develop sales revenues and make a reasonable profit). See supra 
notes 22-25 and accompanying text. 
101 For discussion of the fundamental framework to protect human subjects (e.g., the Com­
mon Rule, the Institutional Review Board (IRB) system, and the Office o f  Human Research 
Protections (OHRP)), see generally MALINOWSKI, BroTECHNOLOGY, supra note 88; IRB REFER­
ENcE Boox, supra note 88. 
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ally predate the pervasive integration of academia and industry as­
sociated with contemporary life science.l02 These regulatory 
regimes rely far too much upon self-compliance by institutions, 
which in turn defer to and depend upon self-compliance by the in­
dividuals engaged in the research that is supposed to be p oliced. 103 
Institutional policies, to the extent meaningful policies even exist,104 
lack specificity regarding permissible relationships and p ractices 
and depend far too heavily upon disclosure to manage conflicts.105 
During the twilight of the Clinton Administration, sweeping 
bioethics reforms were proposed for human clinical trials. For ex­
ample, in May 2000, the Clinton Administration released a plan to 
improve patient safety in clinical trials that calls for clear conflict-of­
interest guidelines for doctors who stand to make money on their 
research. 106 In May 2001, the National Bioethics Advisory Commis­
sion ("NBAC") proposed establishing a single, independent office 
with jurisdiction over all (privately-funded, as well as federally­
funded) domestic human subjects research with a single set of 
rules.l07 Similarly, Dr. Greg Koski, Director of the Office for Human 
Research Protections (OHPR) in HHS, called for the introduction of 
universal standards for IRBs.1os 
President Bush did not appoint leadership for the Food and 
Drug Administration and National Institutes of Health until Febru-
102 See generally Malinowski, Institutional Conflicts, supra note 4, at 69 (noting the integration of 
academia and industry have increased productivity and patient care). 
103 See id. at 64 (explaining the regulatory scheme in the United States and its low level of 
accountability due to reliance on self-compliance). 
104 See generally id. at 66 (describing the majority of United States policies as ineffective). See 
generally id. at 66 (describing the majority of United States policies as ineffective). 
105 See generally Mildred K. Cho et al., Policies on Faculty Conflicts of Interest at US Universities, 
284 JAMA 2203, 2208 (2000) (reporting on an empirical survey indicating that the vast 
majority of research institutions have failed to establish relevant policies because the poli­
cies lack specificity). 
106 See PRESS RELEASE, DEPARTMENT OF HEALTH AND HUMAN SERVICES, SECRETARY SHALALA 
BoLSTERS PROTECTIONS FOR HuMAN RESEARCH SuBJECTS (May 23, 2000), available at http:/ I 
www.hhs.gov / news/press/ 2000pres/20000523.html (noting policies will be developed to 
require disclosure of financial interest in a clinical trial to potential participants); Donna 
Shalala, Protecting Human Subjects-What Must Be Done, 343 NEw ENG. J. MED. 808, 809 
(2000). 
107 See NBAC Recommendations, supra note 90 (proposing the establishment of one indepen­
dent federal office to implement a unified, single set of regulations and guidance), available 
at http: I /bioethics.gov I press/ finalrecomm5-18.html. 
108 See OFFICE FOR HUMAN RESEARCH PROTECTIONS (OHRP) DIVISION OF ASSURANCES AND 
QUAUTY IMPROVEMENT, QUALITY IMPROVEMENT PROGRAM (April 15, 2002), at http : /  /ohrp. 
osophs.dhhs.gov /humansubjects/qip/qipdesc.pdf.; see generally http:/ / ohrp.osophs. 
dhhs.gov /references/ koskibio.pdf (detailing the biography of Dr. Greg Koski). 
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ary and May of 2002, respectively, and subsequently these agencies 
presumably have merely shifted from limbo into a period of transi­
tion.109 Although President Bush has established a new Council in 
Bioethics, thus far, this commission has fixated on the issue of 
human cloning. 1 10 Nevertheless, research continues to rage onward, 
with increased utilization of genetic profiling.I11 Never have as 
many clinical trials been underway, and pharmacogenomics is be­
ing embraced in clinical research to streamline both costs and 
time. 112 In fact, clinical research sponsored by U.S. companies to ad­
vance pharmacogenomics has become a burgeoning, global en­
deavor. Examples include Millennium Pharmaceuticals' 
undertakings in China, which has triggered considerable anxiety 
over human subject participation, 1 1 3  and the joint venture in Japan 
by Variagenics and Covance in November 2000.114 Similarly, Ice­
land's DeCode Genetics, which has collaborations with several U.S. 
interests, has established Encode, a subsidiary specializing in 
pharmacogenomics studies.115 
109 Lester M. Crawford, Jr. was appointed to serve as FDA Deputy Commissioner on Feb. 25, 
2002. See DEPT. oF HEALTH AND HuMAN SERVICES, Lester M. Crawford Jr. Named FDA Dep­
uty Commissioner (Feb. 25, 2002) available at http:/ / www.hhs.gov /news/press/2002pres/ 
20020225.html. Elias Adam Zerhouni was appointed to serve as the Director of the NIH 
on May 20, 2002. See NIH, Zerhouni Assumes Leadership of the National Institutes of Health 
(May 20, 2002), available at http:/  /www.nih.gov /news/pr/may2002/od-20. 
no The President's Council on Bioethics, available at http:/ /bioethics.gov I (describing their 
meeting agendas for February and January 2002, which covered the issue of cloning). 
111  See generally Malinowski, Snake Oil, supra note 3, at 31-33 & app. tbl. 1 (analyzing the uses 
of genetic profiling) .  See also supra Part II. 
112 Malinowski, Institutional Conflicts, supra note 4, at n.1; Malinowski, Snake Oil, supra note 3 
at 33. See also Ann M. Thayer, Biolnformatics for the Masses, CHEMICAL & ENGINEERING 
NEws, Feb. 7, 2000, at 19 (discussing the use of software tools to capture data, which de­
creases costs and improves use of the data collected in research). 
113 See John Pomfret, Harvard Rebukes Head of China Gene Study, WASH. PosT, Aug. 9, 2001, at 
A14 (noting the allegations about a Harvard professor's human-subject research, includ­
ing allegations of taking blood from Chinese farmers without informed consent and not 
providing promised medical care). 
114 See Covance Eyes Pharmacogenomics Business in Japan, CHEMICAL Bus. NEWS BASE, Nov. 24, 
2000, at 1 2  (stating that a joint venhlre between two U.S. companies, Variagenic� and 
Covance, was formed "to provide services to Japanese pharmaceutical producers mter� 
ested in overseas clinical development activities") . 
115 See Decode Genetics, Inc., available at www.decode.com (describing DeCode also as having 
established DeCode Cancer to commercialize diagnostics and therapeutics). 
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3. Conflicts of Interest 
The inclusion of a conflicts of interest provision in the U.S. reg­
ulatory regime-a compliment and extension of regulations for 
technology transfer, to protect human subjects, and to ensure re­
search integrity-places tremendous reliance on self-policing by 
principal investigators and their institutions.116 Trust is a questiona­
ble assurance mechanism to police researchers and institutions ex­
posed to commercial incentives such as royalty and equity 
interests.117 Contemporary commercial influences, including heavy 
dependence upon industry for financing, application expertise, and 
access to a multitude of proprietary enabling teclmologies, also have 
exacerbated a preexisting entanglement of non-financial pressures: 
These pressures, not primarily financial, include the desire for 
faculty advancement, to compete successfully and repetitively for 
sponsored research funding, to receive accolades from professional 
peers and win prestigious research prizes, and to alleviate pain and 
suffering . . .  All of these nonfinancial pressures may generate con­
flicts by creating strong bias toward positive results, and all of them 
may more powerfully influence faculty behavior than any prospect 
of financial enrichment.118 
To support academic-industry synergies moving forward, rele­
vant regulatory regimes must be strengthened. This observation 
has been made all too evident in recent years by controversies in­
cluding the death of human subjects given less than forthright infor­
mation about adverse events in primate and even other human 
studies,119 instances of doctors enrolling and treating patients in 
1 1<> Federal thresholds have been established by the Department of Health and Human Ser­
vices (DHHS), National Institutes of Health (NIHt to define "significant financial interest." 
See 42 C.F.R. § 50.603(1), (3)-(5) (2000) (defining a "significant financial interest" as "any­
thing of monetary value, including, but not limited to, salary or other payments for ser­
vices . . .  equity interests . . .  and intellectual property rights," but not including aggregated 
payments of $10,000 and/ or ownership interest in excess of 5% in a single entity); 21 
C.F.R. §§ 54.1-54.6 (2001) (outlining financial disclosures b y  clinical investigators through 
the FDA). See Malinowski, I11stitutimral Conflicts, supra note 4, at 72-73 and accompanying 
text (addressing both NIH and FDA guidelines). However, the agencies rely heavily upon 
institutions to actually manage conflicts. ld. at 69. 
1 1 7 See ge11erally Malinowski, l1rstituticmal Conflicts, supra note 4, at 58 (discussing that univer­
sity audits are rare in a system of heavy reliance on individual researcher oversight). 
1 111 David Korn, Conflicts of lnterest i11 Biomedical Research, 284 JAMA 2234 (Nov. 1, 2000). 
1 1" Sec Gelsinger v. Trustees of the Univ. of Pa., Case No. 0009018885 (Ct. Com. Pl., Phila. 
County, filed Sept. 18, 2000), at http:/ /www.sskrplaw.com/links/healthcare2.html 
[ .. Gelsinger Complaint"]. Following the death of Jesse Gelsinger, the American Society of 
Gene Therapy (ASGT) prohibited researchers from taking equity interests or stock options 
in companies which sponsor the researchers' gene therapy trials. Furthermore, the Associ­
ation of American Medical Colleges (AAMC) announced the formation of a task force to 
add ress conflicts of interest issues, and the American Medical Association (AMA) adopted 
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clinical studies paid for by the companies they own,120 disputes be­
tween academics and their industry sponsors over data,121 and pres­
sures on universities to loosen conflict-of-interest rules. 122 In the 
absence of significant regulatory reform, escalating commercial 
pressures will increase risks to human subjects and research 
integrity . 123 
B. Metamorphosis of Clinical Research 
Genetic precision in bench research is rapidly spilling over into 
clinical trials, where experimentation and treatment (meaning 
clinical research and clinical care) are integrating.124 Clinical re­
search has entered an era of transparency, meaning that information 
about clinical trials is online and accessible to the general public, 
and the public is seeking access. 1 25 As breakthrough treatments for 
presently untreatable conditions mature in the drug development 
a policy on conflicts of interest calling on all medical centers to develop guidelines to 
avoid perceived and actual conflicts. See AMER. Soc"v OF GENE THERAPY (ASGT), Poucy 
OF THE AMER ICAN SociETY oF GENE THERAPY oN FINANCIAL CoNFLICT OF INTEREST IN 
CLINICAL RESEARCH (2000), at http : /  /www.asgt.org/policy/index.html; AM. MEo. Ass'N, 
COUNCIL ON ETHICAL & jUDICIAL AFFAIRS, CONFLICTS OF INTEREST: BIOMEDICAL RESEARCH, 
Or. E-8.031 (1999), at http : /  /www.ama-assn.org /apps/pf_online/.  . .  TM&hxt_pol=policy 
files/CEJA /E-8.01 .HTM&; Malinowski, btstitu ti01zal Conflicts, supra note 4, at 69-70. 
120 See Gelsinger Complaint, supra note 1 19; see also Sheryl Gay Stolberg, Biomedicine Is Receiv­
ing New Scruti11y as Scimtists Become Entrepreneurs, N.Y. TIMES, Feb. 20, 2000, at A26 (noting 
that according to the FDA, this practice was becoming increasingly pervasive in the field 
of gene therapy prior to the death of Jesse Gelsinger). 
121 
For example, the company Immune Response and medical researchers at the University of 
California at San Francisco and Harvard University have been engaged in a high-profile 
dispute over publication of negative data from the Phase III trial of Remune, an anti-HIV 
drug. See Eric Niiler, Company, Academics A rgue over Data, 18 NATURE BIOTECHNOLOGY 
1235 (Dec. 2000). 
122 See Katherine S. Mangan, Harvard Medical School Will Keep Its Conflict-of-Interest Policies, 
CHRON. HIGHER EDuc., June 9, 2000, at A36 (noting that Harvard University even consid­
ered lessening its relatively strict standards, but then decided against that proposal). In 
fact, Harvard has joined several other renowned medical schools in drafting joint conflicts 
?f interest guidelines. See Katherine S. Mangan, Medical Schools Draft Guidelines for Prevent­
mg Conflicts of Interest, Cl-moN. HIGHER Eouc., Feb. 23, 2001, at A36. 
123 See M 1· k. · · · · Ad . . 
_
a mows 1, lnstztuttonal Conflicts, supra note 4, at 72 (suggestmg that the Bush mm-
�stratlOn continue reforms to improve accountability in biomedical research). See generally 
mfra Part IV. 
124 See M r k. · · · · h a mows 1, Instlf utwna/ Conflicts, supra note 4, at 54 (statmg that webs1tes sue as 
tho�e of the National Institute of Health and the National Library of Medicines provide onlme access to clinical trials, which link patients w i th trials). 
us Th· . 1� transparency is attributable in part to the United States· official, FDA-managed c�tmcal trial web site, nt http:/ /www.clinicaltrials.gov. For additional clinical trial web 
srtes, see supra note 99. 
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pipeline, both patients and providers will more readily look to 
clinical trials for health care options.126 Decisions by the govern­
ment and other payers to cover clinical trial-related medical costs in 
a reliable manner are encouraging this trend. Muddying the thresh­
old between clinical trials and standard of care will have a profound 
impact on professional responsibility, liability, and health care 
finance .127 
C. Genetic Profiling as an Accompaniment to Prescription 
Pharmaceuticals 
The day when the neighborhood pharmacist routinely tailors 
commercially available pharmaceuticals to account for each per­
son's SNP idiosyncrasies may be decades removed. Nevertheless, 
market introduction of genetic tests to make prescription drug 
choices thus far is simply a glimpse into a foreseeable future.128 
Pharmacogenomics129 as a R&D methodology will bring forth mean­
ingful pharmacogenetics130 capabilities. In turn, these capabilities 
will be utilized by the medical community to engage in individually 
tailored health care delivery and prevention with significant health 
outcome improvements.131 Subscriber services to inform individu­
als about the latest SNP identifications that could in1pact their re­
sponses to com mercially available drugs and drug interactions in an 
ongoing manner are already under development.132 Such databases 
and services are presently available to members of the research 
126 See Malinowski, Institutional Conflicts, supra note 4, at 53-54 (describing the public percep­
tion of clinical trials as creating breakthrough treatments). 
127 HEALTH CARE FINANCING ADMIN., MEDICARE CovERAGE Poucv-CLINICAL TmALS, FtNA L 
NATIONAL CovERAGE DECISION, at http:/ /www.hcfa.gov /coverage/8d2.htm; OEP'T OF 
HEALTH & HUMAN SERVS., HEALTH CARE FINANCING ADMIN., HCFA FACT SHEET, MEDI­
CARE CovERAGE RouTINE CosTs oF BENEFICIARIES IN CLINICAL TRIALS (2000), at http: / I 
www.hcfa .gov / medlearn/ ctfsl3.pdf (stating that Medicare beneficiaries would not lose 
their coverage by enrolling in clinical trials in an effort to promote more innovations 
through clinical trials). See also Malinowski, Institutional Conflicts, supra note 4, at 55-56 
(noting that government policy is supportive of clinical care). See generally SusAN QuiNN, 
HUMAN TRIALS: SciENTISTS, INVESTORS, AND PATIENTS IN THE QUEST FOR A CURE (Perseus 
2001) (detailing a case study of the company Autoimmune which emphasized the impact 
of clinical trials on patients awaiting innovative treatments). 
128 Genetic profiling as an accompaniment to drug delivery is made tangible by present appli-
cations of such technology. See supra notes 64-68 and accompanying text. 
129 See supra notes 4-5 and accompanying text. 
130 See supra note 9 and accompanying text. 
131 See supra note 8 and accompanying text. 
132 See supra notes 69-76 and accompanying text. 
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community, and the mission of the ongoing work of the well-fi­
nanced and diligent SNP consortium is to chum out a voluminous 
number of genotype-phenotype (genetic-physical characteristic) 
connections. 133 
The use of pharmacogenomics and pharmacogenetics by the 
health care community will intensify and add new dimensions to 
many standing law and policy issues. These issues include genetic 
exceptionalism in both law and regulation, education of the health 
care provider community, market acceptance, and patient access. 
1. Genetic Exceptionalism 
Predictive genetic tests manufactured and sold to others to per­
form are regulated by the FDA as medical devices.134 However, pre­
dictive genetic tests performed by their manufacturers and made 
available to others as a service, which are known as "homebrew 
tests," escape FDA regulation and are arguably not meaningfully 
regulated otherwise.13S This regulatory exceptionalism was made 
all-too-clear in 1996 and 1997 when several biotech companies en­
gaged in commercializing predictive genetic tests for breast cancer 
premised upon links between the disease and BRCAl and BRCA2 
variations, without data to establish the clinical utility of this con-
133 See THE SNP CoNSORTIUM LTD., SINGLE NucLEOTIDE PoLYMORPHISMS FOR BIOMEDICAL RE­
SEARCH at http: /  /snp.cshl.org (stating that the Consortium's mission is to research and 
publicize SNPs, not that the general public will have access to this scientific information). 
See also Malinowski, Snake Oil, supra note 3, at 32 (explaining that bioinformatics has used 
software to create data libraries). 
134 Medical Device Amendments of 1976, Pub. L. No. 94-295, 90 Stat. 539 (codified as 
amended at 15 U.S.C. § 55 (1994) and in sections of 21 U.S.C.). See Malinowski, Snake Oil, 
supra note 3, at 43-44 (recommending that Congress revise the Medical Devises Act to 
enable and encourage the FDA to regulate gentic tests more broadly). 
135 See Malinowski, Snake Oil, supra note 3, at 44 (explaining the only meaningful federal 
oversight of homebrew testing is under the CLIA, or the Clinical Laboratory Improvement 
Amendments, the scope of which is limited to regulating the proficiency /accuracy of test­
ing and administrative requirements). See generally Anny Huang, FDA Regulation of Genetic 
Tes ting: Institutional Reluctance and Public Guardianship, 53 Fooo & DRUG L.J. 555, 556-57 
(1998) (stating the FDA has repeatedly taken the position that it will not regulate "kits," 
even though it regulates testing services conducted at centers and laboratories). See Ge­
netic Testing Under the Clinical Laboratory Improvement Amendments, 65 Fed. Reg. 
25,928 (May 4, 2000) (announcing that the CLIA Committee recommended the creation of 
a genetic testing specialty); CLINICAL LABORATORY IMPROVEMENT ADVISORY CoMMITTEE 
(CL!AC), GENERAL RECOMMENDATIONS FOR QuALITY ASSURANCE PROGRAM FOR LABORA­
TORY MoLECULAR GENETIC TEsTS (Aug. 31, 1999); SEcRETARY's ADvrsoRY CoMMriTEE ON 
GENETIC TESTING (SACGT), ENHANCING THE OVERSIGHT OF GENETrC TESTS: RECOMMENDA­
TIONS OF THE SACGT (July 2000), available at http:/ /www4.od.nihgov/oba/sacgt.htm. 
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nection for women in general. 136 Consequentially, patient groups, 
bioethicists, and policy makers expressed concern that industry 
would engage in premature commercializa tion of predictive genetic 
tests for a multitude of multigenetic d isorders in a similar man­
ner.137 The outcome was an adverse market response to these initial 
tests and their manufacturers, professional and public criticism, and 
genetic exceptionalism in state and federal law. nH Given that most 
genetic tests have multiple potential uses,139 definitional ambiguity 
is prevalent in this legislation. 140 Therefore, genetic exceptionalism 
may prove a significant market barrier to the commercial availabil­
ity of genetic profiling technologies in general and, consequently, 
for utilization of pharmacogenetics to improve the delivery of 
health care.141 
2. Health Care Provider Competency 
The transition from fee-for-service into managed care has im­
posed time and other commercial pressures on the United States 
136 See Malinowski, Snake Oil, supra note 3, at 36 (stating that the absence of clinical utility can 
lead to test takers unknowingly subjecting themselves to possible over-treatment, false 
assurances, and discrimination by insurers and employers. 
137 See id. at 35-37 (describing the marketing of tests to detect mutations in the BRCAl gene 
"to predict susceptibility to the occurrences of some hereditary forms of breast cancer.''). 
138 See id. at 34-37 (explaining how in the midst of a series of federal legislative and adminis­
trative initiatives, states enacted an entanglement of genetics legislation). For a concise, 
organized overview of the kinds of legislation states have enacted, see William F. Mulhol­
land, II & Ami S. Jaeger, Genetic Privacy and Discrimination: A Survey of State Legislation, 39 
}URIMETRics J. 317, 317-26 (1999) (noting that the most prohibited actions under this legis­
lation include some combination of the following: genetic testing in general; requiring or 
requesting a genetic test or information; disclosing the results of a genetic test to third 
parties without prior informed consent; discharging, refusing to hire, or refusing to pro­
mote by employers on the basis of the results of genetic tests; affecting terms, conditions, 
or disbursement of benefits based upon the results of genetic tests; refusing to consider an 
application; refusing to issue or renew an existing policy; classifying information derived 
from a genetic test as a preexisting condition; charging higher rates or premiums; and 
discriminating charges in brokerage fees or commissions). Exceptions are commonly 
made for genetic testing in a court proceeding and genetic research. Id. at 318-19. 
139 Malinowski, Snake Oil, supra note 3, at n.24 and accompanying text. Consider that a ge­
netic test for over expression of Her2-neu could be used: (1) in a woman with breast cancer 
to determine whether she should consider taking certain medications for treatment, such 
as Herceptin; (2) in a healthy woman with a family history of breast cancer to help assess 
susceptibility to the disease and perhaps to determine whether she should take medication 
as a preventive measure; or (3) perhaps by a potential mother with a family history of 
breast cancer to screen embryos before undergoing in vitro fertilization. 
140 Id. at 28-29 (highlighting that scientific definitions of "predictive genetic testing" work 
relatively well in a regulatory context). 
141 See generally id. at 30. 
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health care con1munity. 142 Even before the spread of managed care 
throughout the 1 990s, concerns were raised about the failure of most 
medical school curricula to educate health care providers to deliver 
care in the midst of the genetics revolution.143 The explosive ad­
vancement of biotechnology from the research bench into the mar­
ket has validated many of these concerns. 144 "In light of the 
towering and still rising wave of information, the all-knowing gen­
eral practicioner is not a contemporary possibility."145 
The advent of pharmacogenomics now may overwhelm the 
medical community with an even more pervasive set of challenges. 
Although managed care gene rail y has embraced diagnostic testing 
and preventive screening, an intense deluge of additional testing as­
sociated with a generation of much more expensive pharmaceuticals 
would prove difficult to absorb. 1 46 Moreover, the market introduc­
tion of a multitude of innovative pharmaceuticals accompanied by 
genetic p rofiling and added decision making, a jolt in pharmaceuti­
cal complexity attributable to genetic precision, changes in long­
standing disease classifications, and the commingling of clinical care 
and ongoing clinical research will necessitate significant changes in 
the delivery of care. Rather than making doctors and nurses assume 
this entire burden, it is likely that pharmacists and non-physician 
clinicians will be stepping into an expanded role in the health care 
process. 
142 See generally Michael J. Malinowski, Capitation, Advances in Medical Technology, and the Ad­
vent of a New Era in Medical Ethics, 22 AM. J.L. & MED. 331, 336 (1996), reprinted in TAKING 
SIDES: CLASHING VIEWS ON CoNTROVERSIAL BIOETHICAL IssuEs (Carol Levine ed., 7th ed. 
1997) (stating that "as a result of third-party payment of health care costs, patient consum­
ers have become indifferent and insensitive to the prices of services and the costs of treat­
ments, seldom considering price and cost even when they undergo elective diagnostic 
tests and surgeries."). 
143 Michael J. Malinowski & Robin J.R. Blatt, Commercialization of Genetic Testing Services: The 
FDA, Market Forces, and Biological Tarot Cards, 71 TUL. L. REv. 1211, 1245-1246 (1997) (ex­
plaining that the current generation of health care providers do not possess the skills to 
interpret predictive genetic tests). 
144 See Michael J. Malinowski, Foreword: Academic-Industry Collaborations in the Clinic, 8 WID­
ENER L. SYMP. J. ii, ii-iii & nn. 1-7 (2001) (commenting how the market is driven by "aca­
demic-industry alliances."). 
145 Malinowski, Institutional Conflicts, supra note 4, at 54. 
146 For an excellent treatment of the health care complexities of clinical application of ad­
vances in human genetics, see generally GENETICS IN THE CLINIC: CLINICAL, ETHICAL, AND 
SociAL IMPLICATIONS FOR PRIMARY CARE (Mary Mahowald et al. eds., 2001) [hereinafter 
GENETICS IN THE CLINIC] . 
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3. Market Acceptance and Patient Access 
Conceivably, the public may embrace and directly pay for se­
lect genetic profiling services-such as screening to anticipate reac­
tions to major pharmaceuticals and to manage drug interactions-to 
the extent necessary to make providing those services commercially 
viable.147 Market acceptance also may be realized in part through 
medical community participation in life science R&D utilizing 
pharmacogenomics. Major medical centers with access to samples 
and patients are positioned to aggressively pursue these opportuni­
ties, and when such institutions embrace technology transfer and 
commercial collaborations, their portfolios of agreements are likely 
to encompass a considerble amount of clinical research.148 
Nevertheless, many in the medical community are more famil­
iar with the confidentiality, privacy, and potential discrimination is­
sues associated with predictive genetic testing than the technology 
itself.l49 Educating the medical community about the multitude of 
intricacies associated with a broad generation of drugs developed 
through pharmacogenomics could prove a daunting challenge for 
the life science industry. Clinical use of most predictive genetic test­
ing requires considerable interpretation, and pharmacogenomics 
147 See supra notes 68-76 and accompanying text (identifying some emerging Internet services, 
including genetic screening services to improve drug reactions and identify potential 
problems from drug interactions). 
148 See Uz Kowalczyk, Lucrative Licensing Deals with Drug, Biotech Firms are Raising Ethics Is­
sues for Hospitals, BosToN SUNDAY GLOBE, Mar. 24, 2002, at Cl (stating "[H]ospitals have 
become increasingly interested, particularly since managed care restricted their income 
during the 1990s and heated competition for patients fostered a more entrepreneurial atti­
tude."); see also Liz Kowalcsyk, Medical Schools Join Forces: Harvard, Others Aim to Give Drug 
Firms Faster OK's on Clinical Trials, BosTON GLOBE, July 28, 2000, at Cl (reporting on an 
alliance between Harvard and four other medical schools to counter the private industry's 
efforts to dominate human research on new medical treatments). Medical academia is 
attempting to reclaim its influence in clinical research, which has been diminished over the 
last decade through the emergence and explosive growth of the global contract research 
organization ("CRO") industry, led by companies such as Covance, Inc., at http: / /www. 
covance.com; Parexel International Corporation, at http:/ /www.parexel.com, and Quin­
tiles Transnational, at http:/ /www.quintiles.com. See Malinowski, Institutional Conflicts, 
supra note 4, at note 30 and accompanying text. Nevertheless, academic institutions' em­
brace of industry relationships has heightened regulatory and ethical hurdles, including 
institutional conflicts. See generally id. For example, NIH concerns led to the demise of 
Boston University's plans to use Framingham Study data in genomics studies. See Vicki 
Brower, Framingham Heart Study Genomics Firm Stops Beating, BioTECHNOLOGY NEw­
SWATCH, Jan. 15, 2001, p .  1 ., 2001 WL 8787439. 
149 Malinowski, Snake Oil, supra note 3, at 35-36 (stating that many medical community insid­
ers think that "the use of predictive genetic testing with clinical utility for many common 
disorders is decades removed from the present realities of managed care."). 
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could add an addi tiona! dimension of complexity to drug prescrib­
ing. 150 The da ngers of over-reliance on genetic profiling include 
over and under dosing and false assurances. These oversights can 
lead to fa ilures to closely monitor drug interactions or to make nec­
essary dosage adjustments and drug substitutes over time. In addi­
tion, the significant streamlining of clinical trials may heighten 
provider dependence on compiled Phase IV data while the 
pharmaceuticals are being taken by patients. Even more fundamen­
tal, introducing drugs genetically tailored to fit only into the eye of a 
traditional disease classification may prove problematic for a medi­
cal provider community accustomed to traditional disease classifica­
tions, cruder pharmaceuticals, and broad off-label use. 
Pharmacogenetics also will have a profound impact on reim­
bursement decision-making and patient access, and set in motion a 
series of market c hanges presently difficult to fully define and mea­
sure.151 Just a few decades ago, prescriptions generally cost less 
than $10, and a prescription charge of $100 would have caused pa­
tients, health care providers, and payers to balk. However, technol­
ogy has elevated costs with capabilities. 152 Pharmacogenomics 
offers the potential of cost savings and human capital returns from 
improved health care outcomes.153 Nevertheless, the precision re­
sulting from meaningful pharmacogenomics suggests industry will 
have to recoup the costs of developing these innovative drugs from 
much smaller patient populations, meaning even higher drug costs 
for those who take the drugs. 154 Pharmacogenomics will also intro­
duce new costs, including genetic profiling, data collection and 
processing, and monitoring services. Given the data collection gen-
150 See generally GENETICS IN THE CLINIC, supra note 1 46; Lee M. Silver, The Meaning of Genes 
and "Genetic Rights" 40 }URIMETRics J. 9, 1 1-12 (1999) (explaining what genes are and how 
they compare to others' genes). 
151 See infra Part IV; see supra Part Ill. See generally Kahn, supra note 22, at 20 (identifying a 
number of market variables that bear upon the market performance of the biotechnology 
and pharmaceuticals sectors). 
152 For example, today's technologies for cancer include Herceptin, a drug that has proven 
helpful for many patients with previously untreatable cases of breast cancer at a cost of 
approximately $20,000 per patient, and a $10,000 wafer chip that delivers chemotherapy 
directly into a patient's brain. See Pam Abramowitz, The Financial Impact of Genomics, THE 
BoNn BuYER, Dec. 13, 2000, p.  18, 2000 WL 30670701. See also Jurna et. al., supra note 33. 
153 See generally Pincowish, supra note 50 and accompanying text. 
154 See Malinowski, Institutional Conflicts, supra note 4, at n.21 (stating that the "use of 
pharmacogenomics, bioinfonnatics, and related technologies will result in pharmaceuti­
cals tailored to individual genetic profiles, streamlined therapeutic use, regulatory ap­
proval and labeling limitations . . . . "). See also Malinowski, FDA Regulation, supra note 20, 
at 224. 
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erated by market use, the dynamic nature of the human genome in 
response to environmental stimuli, and the need to make pharma­
ceutical dosage and drug changes over time, the cost of moni toring 
could prove significant. 
This climate and the raging controversy over drug p ricing sug­
gest that genetic profiling as an accompaniment to drug delivery 
will have to enter the marketplace with sound evidence of clinical 
utility in order to be accepted.155 Widespread medical community 
acceptance is likely to depend heavily upon the safety, efficacy, and 
clinical utility of the pharmaceuticals developed with pharmacoge­
nomics that carry genetic profiling into the marketplace. 1 56 
IV. PROPOSALS FOR LEGISLATIVE AND REGULATORY 
REFORM 
Admittedly, today's life science enabling teclmologies and 
commercial investment in applying those technologies make gaug­
ing tomorrow's health care a speculative endeavor even for ex­
perts .157 Nevertheless, recent history is telling: biotechnology and 
genetic medicine have influenced the delivery of care in jolting 
ways over the last decade.158 Therefore, in the context of 
pharmacogenomics, pragmatism mandates not assuming the luxury 
of time to resolve major law, business, and health care challenges 
associated with this technology. This article has identified many of 
155 Malinowski, Snake Oil, supra note 3, at 41.  See also Milt Freudenheim & Melody Petersen, 
The Drug-Price Express Runs into a Wall, N.Y. TrMEs, Dec. 23, 2001,  at 1 (reporting that 
market resistance to new drugs in the absence of significant clinical utility offsets price 
increases) . 
156 Presumably, the FDA will require precision labeling for drugs developed with heavy utili­
zation of genetic profiling, and the FDA may even require genetic profiling as a pre-condi­
tion for approved market use. For a technical treatment of the FDA's review of new drugs 
and approval process, see MAUNOWSKI, BIOTECHNOLOGY, supra note 88, at ch. 1 1 .  
157 See Kahn, supra note 22, a t  20; Freudenheim & Petersen, Drug-Price Express, supra note 155, 
at 1 (stating that the rise in health insurance premiums and an economic downturn has led 
to an unstable drug market). Cf Malinowski, Snake Oil, supra note 3, at 47 (charting how 
current enabling techniques allow industry players to develop new research possibilities). 
158 In 1995, there were only eight biotech-derived pharmaceuticals on the market. Today, 
there are over 100. For identification of the present drug development pipeline, see http:/ 
/www.phrma.org (site of the Pharmaceutical Researchers and Manufacturers of America 
(PhRMA), the world's leading pharmaceutical trade organization); http:/ /www.bio.org 
(site of the Biotechnology Industry Organization (BIO), the world's leading biotechnology 
industry trade organization). For identification of the biotech drugs on the market in 1995, 
see Michael J. Malinowski & Maureen A. O'Rourke, A False Start? The Impact of Federal 
Policy on the Genotechnology Industry, 13 YALE J .  ON REG. 163, n. 1 (1996). 
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these cha l l enges and en1phasizcd tha t novv is the time to address 
them. 
A prcrn i se i n1pl ied throughout this article is that those en­
ga ged i n  s h a pi ng health law, hea lth pol icy, and bioethics must re­
search and a d d ress the uti l ization of innovative technologies in the 
drug devel opn1ent pipel ine and the transition of resulting technolo­
gies into the delivery of health care in a diligent manner. 159 Argua­
bly, in  many a reas where law and science overlap, the long-standing 
divide between technology and responsive, fact-based, otherwise 
pragmatic, and intelJectually thoughtful law and policy has wid­
ened into an abyss over the last decade or so.160 Given the quicken­
ing pace of advances in contemporary life science through 
bioinformatics and other enabling technologies,161 the divide be­
tween law and life science continues to widen in several now press­
ing areas and with increasingly dire health, economic, policy, and 
ethical consequences, thereby raising more complicated regulatory 
challenges. 162 A generation of unprecedented, often breakthrough, 
life science is now reaching delivery of care and entering a United 
States health care finance system that has been critiqued for decades 
for failing to guaranty a minimum standard of care for the U.S. pop­
ulation.163 The number of uninsured and insufficiently insured has 
risen over the years to reach more than forty million Americans, and 
those ranks continue to expand and include more working Ameri­
cans. 164 Moreover, accurately gauging the entry of specific scientific 
capabilities into health care application, especially under the expan­
sive shadow cast by the unpredictability of advances i n  enabling 
159 See Malinowski, Snake Oil, supra note 3, at 39-41 (discussing "Shared Responsibility for 
Widening the Gap."). 
160 See id. at 39 (commenting that the Ethical, Legal, and Social Implications (ELSI) program of 
the HGP has overlooked the "systemic introduction of predictive genetic testing into 
health care''). 
161 See supra Part I ("Traditional Pharmaceuticals and the Changing Pharmaceutical 
Economy"). 
162 See Michael J. Malinowski, Biotechnologt; in the USA: Responsive Regulation in the Life Science 
Industry, 2 INT'L J. BIOTECHNOLOGY 16 (2000). 
163 See generally Richard D. Lamm, Universal Health Care Coverage: A Two-Front War, 22 J. LE­
GAL MEo. 225, 225-27 (June 2001) (stating that 1 6% of the United States population has no 
health insurance, and that this uninsured population tends to be more sick on average 
than those people with health insurance). 
164 See Arthur Jones, Stretched to the Limit, NAT'L CArn. REP., Feb. 22, 2002, at 3, 2002 WL 
10828411 (explaining that there are approximately forty million uninsured/insufficiently 
insured citizens in the United States and that many of those joining the ranks of the unin­
sured are working Americans). 
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technologies, l6S is a Herculean task.166 The present state of some ar­
eas of relevant law and scholarship suggest that the legal profession 
has yet to engage in a meaningful, ongoing dialogue with those 
pushing out the forefronts of life science R&D and directly engaged 
in health care innovation.l67 
165 See Malinowski, Snake Oil, supra note 3, at 26 (describing how enabling technologies have 
had an explosive impact on biotechnology R&D-perhaps mostly to the surprise of the 
health care community). 
166 See supra note 22 and accompanying text. 
167 Patent law provides a pressing example, for intellectual p roperty policy innately presumes 
insight about and sensitively towards markets, economic reality, and the actual practices 
of technology innovators. Cf PHILIP W. GRUBB, PATENTS FOR CHEMICALS, PHARMACEUTI­
CALS AND BIOTECHNOLOGY: FUNDAMENTALS OF GLOBAL LAW, PRACTICE AND STRATEGY 
(1999) [hereinafter "Patents for Chemicals" ] (noting in the p reface that "in the previous edi­
tion [of this treatise] a number of predictions were made, most of which turned out to be 
completely incorrect."). Arguably, the U.S. patent regime did not anticipate the jolting 
advances in the state of the art introduced by fields such as biotechnology, genomics, and 
bioinformatics over the last several years and, in hindsight, patent criteria may have been 
interpreted too broadly throughout the 1990s. The USPTO responded in January 2001 by 
issuing revised standards for written description and utility in genetics. See Utility Exami­
nation Guidelines, 66 Fed. Reg. 1092, 1092-1099 Oan. 5, 2001) (setting forth specific stan­
dards); Guidelines for Examination of Patent Applications Under .the 35 U.S.C. § 1 12, Pl, 
"Written Description" Requirement, 66 Fed. Reg. 1099 (2001). Ideally, as concern about 
over patenting in biotechnology became a pressing topic in the early 1990s, law academia 
should have responded by undertaking pragmatic field work in the life science sectors, 
demonstrating appreciation for ''real world" implications, and then setting forth insightful, 
sector-sensitive proposals to modify application of traditional patent criteria and practices 
while remaining faithful to these core criteria. Certainly, some of this work was done. See, 
e.g., James Donahue, Note, Patenting of Human DNA Seq ue11ces-Implications for Prenatal 
Genetic Testing, 36 BRANDEIS J. FAM. L. 267, 282 (1997-1998). Nevertheless, even after for­
mer President Clinton and Prime Minister Tony Blair made statements on March 14, 2000 
critical of biotechnology patenting that caused the biotechnology market sector to drop by 
$100 billion over the next 24 hours, some law academics have continued to fail to distin­
guish the information technology sector from the life science sector with meaningful sensi­
tivity reflective of the obvious scientific, economic, and other "real world" differences. See 
Andrew Pollack, Protecting A Favorable Image: Biotechnology Col!cer1zs itt Quandary Over 
Drug Giants, N.Y. TIMES, Apr. 4, 2000, at Cl. See also Mal inowski, Snake Oil, supra note 3, at 
n.22. For example, some have proposed transplanting cornerstone doctrine in copyright 
and trademark such as "fair use," a doctrine proven workable for the information technol­
ogy and publishing sectors, into the body of patent jurisprudence. See Maureen A. 
O' Rourke, Toward a Doctrine of Fair Use in Patent Law, 100 CoLUM. L. REv. 1177, 1236-1237 
(2000). While expansion of mechanisms already present in the patenting regime such a s  
the reexamination procedure may prove desirable and even critical for the advancement o f  
life science, analysis should embody understanding o f  and appreciation for the technical, 
pragmatic differences between life science R&D and other sectors that rely much more 
heavily on copyright and trademark protection. The extraordinary rate of failure, cost, 
time, and other risks-such as regulatory uncertainty and market unpredictability-asso­
ciated with life science R&D readily distinguish the sector. See GRuBe, supra note 167, at 
225-226 (highlighting the perspective of a European patent attorney with decades of prac­
tice experience in multiple, technology-driven sectors). As demonstrated in March 2000 
and recognized by the National Institutes of Health in its August 2001 report, significantly 
MALINOWSKI 61 
One might argue, therefore, that there is a moral imperative in 
addition to a professional obligation to bridge law and policy with 
meaningful fieldwork (meaning laborious fact gathering) in both life 
science R&D and health care delivery, and to thereby proactively 
address foreseeable health law, policy, and bioethics challenges in a 
pragmatic manner. Given the life and death ramifications of health 
law and policy, in addition to academic theory and intellectual ca­
pabilities, those in the field must and a pproach issues with a "criti­
cal mass" of practical knowledge in: (a) regulation and legislation 
along the entire R&D continuum from the laboratory bench to the 
health care marketplace, (b) the economic and other realities of life 
science R&D, (c) health care delivery, and (d) the health care 
marketplace. 
In recent scholarship, this author and others have proposed 
regulatory /law and institutional reforms to address many of the 
challenges that will be exacerbated by the advent of pharmacoge­
nomics, including access to human biological materials, protection 
of human subjects, conflicts of interest, and commingling of clinical 
care and clinical research.168 The reforms proposed by this author 
include revisiting the present state legislative scheme encompassing 
predictive genetic testing, 169 introducing reliable federal information 
management systems for both human subject protection and tech­
nology transfer,170 coupling federal oversight capabilities with en­
forcement (such as compliance audits in both human subject 
protection and technology transfer),171 and bridging grant compli­
ance and technology transfer within health science institutions.172 
weakening the patent regime would have dire consequences on the behavior of those who 
invest their careers-whether based in academia or industry-in pharmaceuticals, and 
presumably even more dire consequences for the patients and their families and friends 
who await their commercial development and availability. See generally DEr'T HEALTH & 
HuMAN SERvs., NAT'L INsT. oF HEALTH, NIH RESPONSE ro THE CoNFEHENCE REPORT RE­
QUEST FOR A PLAN TO ENSURE TAXPAYERS' INTERESTS ARE PJ{OTECTED (July 2001), available at 
http : /  /www.nih.gov /news/070101wyden.htm. But see Arti K. Rai, Tire Information 
Revolution Reaclzes Pharmaceuticals: Balmzcing Innovation I11centives, Cost, & Access in tlze Post­
Genomics Era, 2001 U. ILL. L. REv. 173, 1 78-80 (2001) (proposing a curtailment of patent 
rights premised on cost savings attributable to use of pharmacogenomics). 
168 See generally Michael J. Malinowski, Symposium, Conflicts of Interest in Clinical Research: 
Legal and Ethical Issues, 8 WIDENER L. SYMP. J. 47 (2001); Malinowski, Snake Oil, supra note 
3, at 41-46 (explaining his thesis in ''A Proposal For Regulatory Reform''). 
169 See generally Malinowski, Snake Oil, supra note 3, at 41. 
170 See generally Malinowski, Institutional Coriflicts, supra note 4, at 69-73 (suggesting new 
changes in "Proposals for Reform"). 
171 ld. 
ln Jd. 
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This article has framed a series of additional questions which 
culminate in the following: Given opportunities to introduce more 
meaningful preventive care and to improve health care outcomes 
through commercialization of pharmacogenomics, to what extent 
should the legal and health care environments be made more wel­
coming to this technology to accelerate its widespread use? Even if 
this technology introduces significant short-term costs, should these 
costs be absorbed by a health care system already failing to cover 
millions of citizens? If yes, then at what price? Consider tha t by 
shattering traditional disease classifications, 173 raising the costs of 
pharmaceuticals,l74 and introducing a genetic profiling element to 
drug prescribing and, more generally, to the delivery of care,175 
pharmacogenomics is likely to push United States health care into 
an era of much more pervasive and extreme tiering of coverage and 
access. Also, given that under such circumstances many genetic 
profiling services may be sought and purchased directly by the p ub­
lic,176 it is time to consider introducing w orkable yet meaningful 
safeguards for direct communication between the public and com­
mercial providers of genetic profiling services.177 
The medical, life science, and legal communities must work 
through the entanglement of variables encompassed by these ques­
tions to come up with algorithms that work on a collective level, 
especially since the United States continues to lack reliable federal 
regulatory oversight of predictive genetic testing services.178 Crite­
ria must be developed to guide health care providers, the public, 
and payers to make decisions about clinical utility and responsible 
medical use of genetic profiling technologies. For example, al­
though meaningful genetic profiling capabilities presumably will b e  
developed and introduced in a sporadic manner over the next few 
decades, genetic profiling ultimately should prove as pervasive as 
1 73 See Malinowski, Institutional Conflicts, supra note 4, at n.21; see also Malinowski, FDA Regu­
lation , supra note 20, at 224. 
174 See Malinowski, Institutional Conflicts, supra note 4, at n.21 (explaining that cost hikes can 
impede industry innovation). 
175 See generally Malinowski, Snake Oil, supra note 3, at 31 (commenting that individualized 
medical treatment is a notion "decades removed"). 
176 See supra note 132 and accompanying text. 
177 Melody Petersen, TV Ads Spur a Rise in Prescription Drug Sales, N.Y. TIMES, Mar. 8, 2002, at 
C13. Cf Malinowski, Snake Oil, supra note 3, at 34; 
178 For a thoughtful discussion of the complexities of using genetics in the clinic, see generally 
GENETICS IN THE CLlNIC, supra note 145. 
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genetics in human health. 1 79 During the interim, law should be used 
to ensure that the basic tenets of health insurance, meaning pooling 
and disbursement of risks across the population, are adhered to. 
Sight must also not be lost of the fact that proliferation of under­
standing about human genetics, widespread genetic testing, and the 
resulting flow of information should make genetics a "wash" for the 
purposes of health insurance payers. Heavy utilization of 
pharmacogenomics in drug development, coupled with proactive 
regulatory, other law, and health policy reforms identified through­
out this article, should quicken our transition through the awkward 
period of introduction and into the future of health care. 
CoNcLusioN 
The complexities associated with commercialization of 
pharmacogenomics are extraordinary. This article has identified 
and discussed many of these complexities, including those associ­
ated with the changing pharmaceutical economy, trends in pharma­
ceutical R&D, and implications for the delivery of health care 1nd 
the roles of patients, research subjects, and providers. 
Nevertheless, pharmacogenomics introduces tremendous op­
portunities to improve health care, realize some immediate cost sav­
ings (for example, reducing the incidents of adverse reactions to 
pharmaceuticals), and increase human health and capital. There­
fore, the legal, medical, and life science communities must rise to 
the challenge of working through the complexities associated with 
pharmacogenomics rather than continuing to assume the luxury of 
time or simply damning the endeavor and looking away. 
179 See Malinowski, Snake Oil, supra note 3, at 33-41 (considering "The Consequences of Ge­
netic Exceptionalism''). 
